Copyright
©The Author(s) 2020.
World J Gastroenterol. Aug 21, 2020; 26(31): 4718-4728
Published online Aug 21, 2020. doi: 10.3748/wjg.v26.i31.4718
Published online Aug 21, 2020. doi: 10.3748/wjg.v26.i31.4718
Table 4 Surgical treatment, tumor characteristics and survival
Ref. | Surgery for all patients (LR vs OLT)1 | TNM | 1-yr survival cancer patients | Recurrence |
Ammori et al[27] | 50% vs 50% | No data | 33% | 0% |
De Kerckhove et al[19] | 0% vs 100% | No data | 66% | 33% |
Kassahun et al[21] | 87% vs 0% | No data | 0% | 33% |
Habib et al[17] | 0% vs 100% | No data | 0% | No data |
Bockhorn et al[30] | 83% vs 17% | n = 1 pT1, n = 1 pT2 | 66% | 0% |
Millwala et al[5] | 0% vs 100% | No data | 0% | No data |
Ulrich et al[3] | 90% vs 10% | No data | 0% | No data |
Hori et al[24] | 0% vs 100% | No data | No data | No data |
Lendoire et al[13] | 91.6% vs 0% | No data | 100% | No data |
Mabrut et al[20] | 75% vs 18.9% | n = 6 R0, n = 1 peritoneal seeding | 33% | 50% |
Moslim et al[12] | 22% vs 78% | No data | 0% | 33%, 66% tumor progression |
Fahrner et al[25] | 90% vs 10% | n = 1 pT1N1, n = 2 pT2, n = 1 pT3 | 100% | 75% |
- Citation: Fahrner R, Dennler SG, Inderbitzin D. Risk of malignancy in Caroli disease and syndrome: A systematic review. World J Gastroenterol 2020; 26(31): 4718-4728
- URL: https://www.wjgnet.com/1007-9327/full/v26/i31/4718.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i31.4718